

Cancer

A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors

Trial Status Completed	Trial Runs In 6 Countries	Trial Identifier NCT03264066 2017-000794-37 WO39760
----------------------------------	-------------------------------------	--

The source of the below information is the publicly available website *ClinicalTrials.gov*. It has been summarised and edited into simpler language.

Trial Summary:

This is a study to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab in participants with advanced solid tumors including the following cohorts: squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma (UC), and renal cell carcinoma (RCC).

Hoffmann-La Roche Sponsor	Phase 2 Phase
-------------------------------------	-------------------------

NCT03264066 2017-000794-37 WO39760
Trial Identifiers

Eligibility Criteria:

Gender All	Age ≥ 18 Years	Healthy Volunteers No
----------------------	--------------------------	---------------------------------